gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study

E. Van Cutsem, T. Yoshino, H. J. Lenz, S. Lonardi, A. Falcone, M. L. Limon, M. P. Saunders, A. Sobrero, E. Maiello, Y. S. Park, R. Ferreiro Monteagudo, Y. S. Hong, J. Tomasek, H. Taniguchi, F. Ciardiello, J. Hocke, Z. Oum'hamed, S. Vlassak, M. Studeny, J. Tabernero

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)vi559
JournalAnnals of Oncology
Volume27
DOIs
Publication statusPublished - Oct 1 2016

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this